Casper 2015.

Trial name or title	INCA trial
Methods	Double‐blind, placebo‐controlled clinical trial
Participants	People with liver cirrhosis and ascites
Interventions	Group 1: norfloxacin 400 mg once daily Group 2: placebo once daily
Outcomes	Mortality, spontaneous bacterial peritonitis, other clinically significant infections, duration of unscheduled cirrhosis‐associated hospitalisation within 12 months
Starting date	February 2014
Contact information	Dr Marcus Casper (Email: markus.casper@uks.eu)
Notes	German Clinical Trials Register DRKS00005616; EU Clinical Trials Register EudraCT 2013‐001626‐26